Action - AXN

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,1218

Prix Achat

Prix Vente

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

0,1218

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265%

Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265% Direct-To-Customer Sales Program Helps Raise Gross Margins To 79% PR...

Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer

Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer PR Newswire FOSTER CITY, Calif., Feb. 1, 2016 FOSTER CITY, Calif., Feb. 1, 2016...

Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai

Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai PR Newswire JERSEY CITY, N.J., Dec. 10, 2015 JERSEY...

Aoxing Pharma Announces Opening Of Government Funded Drug Research Center

Aoxing Pharma Announces Opening Of Government Funded Drug Research Center PR Newswire JERSEY CITY, N.J., Dec. 4, 2015 JERSEY CITY, N.J., Dec. 4...

Aoxing Pharma Announces Resignation of CFO

Aoxing Pharma Announces Resignation of CFO PR Newswire JERSEY CITY, N.J., Dec. 4, 2015 JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc. PR Newswire NEW YORK...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aoxing Pharmaceutical, Inc. - AXN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aoxing Pharmaceutical, Inc. - AXN PR Newswire NEW YORK, Dec...

Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million

Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million Direct-To-Customer Sales Program Helps Raise Gross Margin To 80...

Drug Manufacturers - Major Stocks on the Move -- GlaxoSmithKline, Sanofi, Aerie Pharma, TherapeuticsMD, and Aoxing Pharma

Drug Manufacturers - Major Stocks on the Move -- GlaxoSmithKline, Sanofi, Aerie Pharma, TherapeuticsMD, and Aoxing Pharma PR Newswire NEW YORK...

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year PR Newswire JERSEY CITY, N.J., May 15, 2013...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

AXN - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 0,1218

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
IORIncome Opportunity Realty Investments	US$ 24,00 (35,21%)	2
BURUNuburu Inc	US$ 0,2289 (34,65%)	23,05M
RVPRetractable Technologies Inc	US$ 0,92 (27,78%)	16
KNWKnow Labs Inc	US$ 2,53 (10,00%)	1,91k
TICAcuren Corporation	US$ 13,30 (9,83%)	331
VTECVanguard California Tax Exempt Bond ETF	US$ 79,01 (-20,60%)	9
SEGSeaport Entertainment Group Inc	US$ 19,01 (-14,18%)	4
DCORDimensional US Core Equity 1 ETF	US$ 55,01 (-9,69%)	1
NVOXDefiance Daily Target 2x Long Nvo ETF	US$ 8,10 (-9,60%)	14,55k
SATXSatixFy Communications Ltd	US$ 1,05 (-9,48%)	115
BURUNuburu Inc	US$ 0,2289 (34,65%)	23,05M
BILSPDR Bloomberg 1 to3 Month T Bill ETF	US$ 91,535 (0,01%)	5,81M
SGOViShares 0 to 3 Month Treasury Bond ETF	US$ 100,45 (0,00%)	3,36M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 4,75 (0,00%)	3,34M
ETHU2x Ether ETF	US$ 2,02 (-6,91%)	2,85M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Aoxing Pharmaceutical Company New (delisted) (AXN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

AXN Dernières nouvelles

Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265%

Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer

Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai

Aoxing Pharma Announces Opening Of Government Funded Drug Research Center

Aoxing Pharma Announces Resignation of CFO

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aoxing Pharmaceutical, Inc. - AXN

Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million

Drug Manufacturers - Major Stocks on the Move -- GlaxoSmithKline, Sanofi, Aerie Pharma, TherapeuticsMD, and Aoxing Pharma

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year

AXN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Aoxing Pharmaceutical Company New (delisted) (AXN) Cours

Aoxing Pharmaceutical Company New (delisted) (AXN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

AXN Dernières nouvelles

Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265%

Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer

Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai

Aoxing Pharma Announces Opening Of Government Funded Drug Research Center

Aoxing Pharma Announces Resignation of CFO

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aoxing Pharmaceutical, Inc. - AXN

Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million

Drug Manufacturers - Major Stocks on the Move -- GlaxoSmithKline, Sanofi, Aerie Pharma, TherapeuticsMD, and Aoxing Pharma

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year

AXN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE